27.11.2013 • NewschemicalsMerckMerck Serono

Germany’s Merck Adds Israeli R&D Partners

German chemicals and pharmaceutical group Merck KGaA has added two new partners, the newly created Metabomed and the start-up ChanBio, to its €10 million Merck Serono Israel Bioincubator research partnership focused on pre-seed and seed opportunities arising in Israel.

Metabomed, established by scientists at Tel Aviv University and the Technion Israel Institute of Technology, specializes in cancer metabolism and computational biology. ChanBio plans to concentrate on discovery of antibodies selective for ion channels considered to be significant therapeutic targets for treatment of multiple sclerosis (MS).

Strategic investments in external innovation are key elements of Merck's strategy, said Stefan Oschmann, managing board member responsible for pharmaceuticals. "Our MS Ventures fund demonstrates our commitment to creating long-term relationships with and tapping into the innovative entrepreneurial spirit of biotech companies," he added.

Merck recently increased its stake in Jerusalem-based Qlight Nanotech and said it may apply with "selected Israeli partners" for research grants in the Nofar program of Israel's Ministry of Industry and Trade.

The company's biopharmaceuticals arm, Swiss-based Merck Serono, earlier this month signed a memorandum of understanding to cooperate with Israeli biotech firm Kadimastern, which develops human pluripotent stem-cell related products. The aim is to find new compounds as remyelinating agents for MS and possibly to expand the collaboration into treatments for amyotrophic lateral sclerosis (ALS), popularly known as Lou Gehrig's disease.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.